Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)

Tibor A Zwimpfer; Dinuka Ariyaratne; Sian Fereday; Nadia Traficante; Catherine J Kennedy; Kathryn Alsop; George Au-Yeung; Michael Friedlander; Anna Defazio; David DL Bowtell; Dale W Garsed

Journal article

Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)

Tibor A Zwimpfer, Dinuka Ariyaratne, Sian Fereday, Nadia Traficante, Catherine J Kennedy, Kathryn Alsop, George Au-Yeung, Michael Friedlander, Anna Defazio, David DL Bowtell, Dale W Garsed

International Journal of Gynecological Cancer | Elsevier BV | Published : 2026

DOI: 10.1016/j.ijgc.2025.103076

University of Melbourne Researchers

Julie Fereday Author

Nadia Traficante Author

Kathryn Alsop Author

George Au-Yeung Author

Related Projects (1)

UNDERSTANDING ADVERSE AND EXCEPTIONAL OUTCOMES IN OVARIAN CANCER

Most women with high-grade serous ovarian cancer (HGSC) die within five years of diagnosis, as tumours often develop chemotherapy resistance..

Grants

Awarded by Ovarian Cancer Australia

Awarded by Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Awarded by Medical Research and Materiel Command

Awarded by National Health and Medical Research Council

Awarded by Ovarian Cancer Research Foundation

Keywords

6.4 Surgery

Patient Safety

3211 Oncology and Carcinogenesis

Women'S Health

Clinical Research

Ovarian Cancer

32 Biomedical and Clinical Sciences

Cancer

Rare Diseases

Orphan Drug